Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord blood-derived PRP versus hyaluronic acid for knee osteoarthritis
IRCT20211102052944N2Phase 2Completed
- Sponsor
- Royan Cord Blood Bank
- Start
- Apr 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, single-blind trial of umbilical cord blood-derived platelet-rich plasma and hyaluronic acid in knee osteoarthritis (OA) (2 arms), sponsored by Royan Cord Blood Bank. Primary endpoints: Adverse events, Serious adverse events and 4 more. Started Apr 2023; status: completed.
02
Drugs
umbilical cord blood-derived platelet-rich plasmahyaluronic acid
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on IRCT20211102052944N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211102052944N2.